CDKN2A and central nervous system cancer: conducted a systematic review of nine studies analyzing a total of 2,193 IDH-mutant gliomas, concluding that homozygous deletion of CDKN2A was a significant predictor of both shorter progression-free and overall survival in astrocytomas.